Facebook Tracking Image

National Comprehensive Cancer Network

Educational Events & Programs

NCCN 2020 Annual Conference Posters


Best Practices in Implementation and Use of Clinical Practice Guidelines

9. Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making
Barbara Oureilidis-DeVivo, PhD, Westmont College

19. Direction of Developing Cancer Survivorship Guidelines in Japan: An Expert Panel’s Consensus
Yutaka Matsuoka, MD, PhD, National Cancer Center Japan

26. Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50
Robin M. Lally, PhD, MS, RN, AOCN, FAAN, Fred & Pamela Buffett Cancer Center
Member Institution

34. Aligning Genetic Panel Utilization with Clinical Practice Guidelines Through Education
Jeremy J. Day-Storms, PhD, MA, Avalon Healthcare Solutions

35. Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of   Netupitant/Palonosetron (NEPA) vs. a 3-day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
Rudolph Navari, MD, PhD, FACP, O'Neal Comprehensive Cancer Center at UAB
Member Institution

42. Metastatic Renal Cell Carcinoma and Immunotherapy Experience in a Third Level Hospital in Mexico City
Benigno Emmanuel Rodríguez Soto, MD, Centro Medico ABC

50. Relative Risk of Various Endocrinopathies Associated with the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Nusrat Jahan, MD, Texas Tech University Health Sciences Center School of Medicine

94. Prescriber-Assigned Febrile Neutropenia and Emetic Risks Compared to the NCCN Risk Classification for Cancer Treatment Regimens
Kimberly Rose Hedstrom, PharmD, eviCore Healthcare

95. Pilot Testing of InheRET™, an Online Tool to Facilitate NCCN Guideline®-Compliant Referrals for Cancer Genetic Counseling and Increase Access to Care
Amanda Cook, BA, InheRET, Inc.

98. Safety and Financial Analysis of Outpatient Dose-Adjusted EPOCH for B-cell Lymphoma at a Tertiary Comprehensive Cancer Center
Wenhui Li, PharmD, Moffitt Cancer Center
Member Institution

99. Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R Model, 4R = Right Information/Care/Patient/Time
Della F. Makower, MD, Northwestern University Feinberg School of Medicine
Member Institution

105. A Systematic Review and Meta-Analysis on Mucocutaneous Toxicities Associated with Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma
Nusrat Jahan, MD, Texas Tech University Health Sciences Center School of Medicine

106. Targeted Drug Delivery (TDD) for Cancer-Related Pain: Emerging Evidence
Lisa M. Stearns, MD, Center for Pain and Supportive Care

118. International Adaptation of the Resource-Stratified NCCN Frameworks for Breast, Cervical and Rectal Cancers in Bolivia
Steven Schuetz, MD, Northwestern University Feinberg School of Medicine
Member Institution

125. Comparative Study Between the Clinical Effect of Palonosetron and Granisetron as Antiemetic Therapy for Patients Receiving Highly Emetogenic Chemotherapy Regimens
Mohamed Mahrous, Msc, Tanta University

127. Evaluation of Guideline Adherence in Colorectal Cancer Management in a Private Clinic in Lima, Peru
Karina Mayra Aliaga, MD, Oncosalud

132. Impact of Preoperative Biliary Drainage on Postoperative Outcome for Obstructive Jaundice Patients
Zhihui Gao, MD, Zhongshan Hospital Fudan University

Bioinformatics/Information Technology Sciences

27. A Digital Solution to Enable Improved Implementation and Usability of NCCN Guidelines®
Chaohui Guo, PhD, Roche Diagnostics

62. Comparison of Treatment Plans Feasible Through AI Enabled Multidisciplinary Online Tumor Board Solution vs. NCCN Based Clinical Decision Support System (CDSS)
Naresh Ramarajan, MD, Navya

Clinical Oncology

2. Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated with Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers
Lida Mina, MD, Banner MD Anderson cancer Center

3. Patient (Pt)-Reported Outcomes (PRO) in Patients with HER2-Negative Locally Advanced/Metastatic Breast Cancer (LA/mBC) and a Germline BRCA1/2 Mutation (gBRCA1/2 mut) Receiving Talazoparib vs. Physician’s Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups
Sara A. Hurvitz, MD, University of California Los Angeles
Member Institution

4. The Prognostic and Predictive Significance of Joint Investigation of Tumor Marker CA 15-3 and Vitamin D in Breast Cancer Patients
Jamil A. Aliyev, National Center of Oncology of Azerbaijan

5. Role of TUBB3 Gene Expression in Early and Advanced Breast Cancer Stage Formulation
Elchin B. Mansurov, PhD, National Center of Oncology of Azerbaijan

6. Characteristics of Gynecological Anamnesis and its Prognostic Role in Azerbaijani Women with Breast Cancer
Sevinj E. Rahimzade, PhD, National Center of Oncology of Azerbaijan

12. Impact of Treating Physician on Late Treatment Related Morbidity – A Secondary Analysis of a Phase III Randomized Controlled Study in Localized Prostate Cancer
Shawn Malone, MD, The Ottawa Hospital Cancer Centre

15. Comparison of a Single Dose Immediate Instillation of Mitomycin C 20mg Versus 40mg in Prevention of Tumour Recurrence After Resection of Non Muscle Invasive Bladder Cancer
Shree Vishnu Siddarth, MS, MCh, Amrita Institute of Medical Sciences and Research Centre

16. Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study
Sai-Ching Yeung, MD, PhD, The University of Texas MD Anderson Cancer Center
Member Institution

18. Plinabulin: A Potent Inducer of Haptoglobin Production for the Prevention of Tissue Iron Overload in Patients Receiving Blood Transfusions Chronically
Ramon Mohanlal, MD, PhD, BeyondSpring Pharmaceuticals, Inc.

20. Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol free     Melphalan (Evomela®) and Generic Melphalan
Ko Maung, MD, Duke University Hospital>
Member Institution

21. A Study of Pathological Characteristics of Malignant Cribriform Prostatic Lesions
Tam Bui, MD, Ho Chi Minh City University of Medicine and Pharmacy

23. Late Dosing of Leuprolide and Testosterone Levels >20NG/Dl in Prostate Cancer Patients
Przemyslaw Twardowski, MD, TOLMAR Pharmaceuticals

25. Factors Influencing Survival of Patients Treated for Spinal Metastases at a Regional Cancer Center in Appalachia
Hassaan Jafri, MD, Joan C. Edwards School of Medicine at Marshall University

29. First US Prospective Evaluation of Performance of 64Cu DOTATATE PET/CT in Somatostatin Expressing Neuroendocrine Tumors
E. S. Delpassand, MD, Excel Diagnostics and Nuclear Oncology Center

30. Comparative Efficacy, Safety and Acceptability of Single-Agent Poly (ADP-ribose) Polymerase (PARP) Inhibitors in BRCA Mutated HER2-Negative Metastatic or Advanced Breast Cancer: A Network Meta-Analysis
Ju Wang, MD, Third Military Medical University Southwest Hospital

43. Clinical Utility of Encyclopedic Tumor Analysis to Treat Breast Cancer Patients Who Have Failed Standard of Care Treatments
Dadasaheb Akolkar, PhD, Datar Cancer Genetics Limited

44. Data From Electronic Prior Authorization Supports Real-world Evidence Generation: Contemporary Changes in the Treatment of a NSCLC
Henry Henk, PhD, OptumLabs

48. Radiotherapy-Induced Malignancies in Breast Cancer Patients with Pathogenic Germline Variants TP53 in an R337H-Mutation Enriched Cohort
Vanessa Petry Helena Bragaia, MD, Universidade de Sao Paulo Instituto do Cancer do Estado de    Sao Paulo

57. Laparoscopic Microwave Ablation for the Treatment of Primary and Metastatic Liver Malignancies
Adrian Legaspi, MD, Palmetto General Hospital

59. Time is On Our Side: Concomitant Needle Biopsy and Wire-Free Localization of Axillary Lymph Nodes May Decrease Redundant Preoperative Needle Localization in BI-RADS 5,6 Breast Cancer Patients
Mary Hayes, MD, Memorial Healthcare System

61. The HER2 FISH Ratio is a Predictor of Pathologic Complete Response Among Patients with HER2+Breast Cancer Receiving Neoadjuvant Anti-HER2 Doublet Therapy Without Chemotherapy
Eric Lander, MD, Vanderbilt University Medical Center
Member Institution

63. Targeting TGF-β in Ovarian Cancer Results in Decreased Tumor Burden and Improved TCell Immune Response
Rebecca Arend, MD, University of Alabama at Birmingham
YIA, Member Institution

69. Sex-Based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma
Andrew R. Barsky, MD, Abramson Cancer Center at the University of Pennsylvania
Top Abstract, Member Institution

74. Optimal Timing of Radical Surgery from Diagnosis in Muscle Invasive Bladder Cancer (MIBC)
Saurabh Parasramka, MD, University of Kentucky Medical Center
Top Abstract

79. A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis
Dwight Owen, MD, MS, Ohio State University
Member Institution

92. Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma
Audrey Demaree, PharmD, Adaptive Biotechnologies

93. Initial Experience of Robotic Assisted Colorectal Surgery in a Community Hospital
Adrian Legaspi, MD, Palmetto General Hospital

102. Factors Associated with the Uptake of Adjuvant Pertuzumab in Patients with Stage I-III HER2-Positive Breast Cancer: The University of Colorado Cancer Center Experience
Meghan J. Mooradian, MD, University of Colorado School of Medicine
Member Institution

108. A Founder CHEK2 Pathogenic Variant in Association with Kidney Cancer
Kassi Brooks, MS, Beacon Medical Group

111. Effect of Tumor Grade on Neoadjuvant Treatment Outcome in Esophageal Cancer
Jordan McDonald, BS, USF Health Morsani College of Medicine

112. A Case Series of Ectopic Cushing Syndrome in Atypical Lung Carcinoid
Neha Verma, MD, Essen Medical Associates

117. Prognostic Factors in Major Salivary Gland Tumors Treated with Adjuvant Radiation Therapy
Jung Julie Kang, MD, PhD, Memorial Sloan Kettering Cancer Center
Member Institution

119. Comparative Outcomes of Patients with Loco regional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated with Definitive Therapy
Cole Friedes, BS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Member Institution

128. National Cancer Institute Experience with Generic Anastrozole (Anastrodex, Hikma) in Newly Diagnosed Postmenopausal Female Egyptian Patients with Low Burden Visceral Metastatic Breast Cancer
Mohamed Ali Maher, MS, National Cancer Institute Egypt

130. Incidence and Potential Predictors of Thromboembolic Events in Epithelial Ovarian Carcinoma Patients During Perioperative Period
Qingqing Zhou, MSCR, The First Affiliated Hospital of University of Science & Technology of China

131. Evaluation and Analysis of Postoperative Complications After Primary Cytoreduction for 47 Cases of Advanced Epithelial Ovarian Cancer at Stage IIIc and IV
Ying Zhou, MD, The First Affiliated Hospital of University of Science & Technology of China


8. Gene Silencing: Another Mechanism of Resistance?
Jacob J. Adashek, DO, Moffitt Cancer Center
Member Institution


36. Hypertensive Disorders of Pregnancy and Subsequent Breast Cancer Risk
Grace Choong, MD, Mayo Clinic Cancer Center
Member Institution

38. Clinicopathological Features as a Predictor of Female Triple-Negative Breast Cancer Metastasis and Survival in the United States, 2010-2015: A Logistic Regression Model From NCI Surveillance, Epidemiology and End Results (SEER) Database
Zikun Wang, MPH, Indiana University Health Methodist Hospital

55. Breast Cancer at Mount Saint John’s Medical Centre-Mapped
Nandan Shanbhag, MD, Mount Saint John’s Medical Centre

87. Cancer Perception, Myths and Disparities Among Turkish Population: A Qualitative Study
Mustafa Cetiner, MD, Acibadem Maslak Hospital

Outcomes and Health Services Research

1. The Promotion of Exercise Oncology as a Standard Part of Clinical Practice
Karen Wonders, PhD, Maple Tree Cancer Alliance

13. Years of Potential Life Lost Due to Cervical and Uterine Cancer Deaths in the United States, 2000-2016
Chizoba Nwankwo, PhD, Merck & Co., Inc.

14. The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network
Scott Paulson, MD, McKesson Life Sciences

17. Cancer Patients and Family Caregivers as a Unit of Care
Hui Ling Chen, BSN, University of Toledo

24. Cost Comparison of PARP Inhibitors in Women with Ovarian Cancer (OC) in the US HealthCare Market
Ali McBride, PharmD, MS, BCOP, University of Arizona Cancer Center

28. Use of the NCCN Distress Thermometer to Identify and Address Distress During a Telemedicine Visit with Rural Head and Neck Cancer Survivors
Pamela DeGuzman, PhD, University of Virginia

31. Granulocyte Stimulating Colony Factor Use, Characteristics and Treatment Patterns in the United States: An Updated Analysis by the Biologics and Biosimilars Collective Intelligence Consortium
Catherine Lockhart, MS, PharmD, PhD, Biologics and Biosimilars Collective Intelligence Consortium

33. Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed with Small Cell Lung Cancer
Junji Lin, PhD, Concerto Health AI

37. Determinants of Time to Treatment Initiation in Metastatic Cancers
Christopher Black, PhD, Merck & Co., Inc.

40. Impact of Social Determinants of Health on Unplanned Acute Care Service Utilization for Patients with Hematologic Malignancies
Kai Zu, MD, Janssen Scientific Affairs, LLC

46. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study
En Cheng, MD, MSPH, Yale University

47. The Direct Referral Unit: Clinical Outcomes and Experience with a Specialized Urgent Care Center for Oncology Patients
Christopher D'Avella, MD, Fox Chase Cancer Center

49. A Systematic Literature Review of First-Line (1L) Treatments for Patients with MGMT (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) Methylated and Unmethylated Glioblastoma Multiforme (GBM)
Gautamjeet Mangat, MS, Bristol-Myers Squibb

51. Association of Patient Clinico-Genomic Characteristics with Tumor Mutational Burden in Small Cell Lung Cancer: An Observational Study
Sumesh Kachroo, PhD, Merck & Co., Inc.

52. Quantifying Patient Preferences for Attributes Associated with First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Brian Seal, PhD, MBA , RPh, AstraZeneca Pharmaceuticals, LP

54. Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia
Stephenie Kennedy-Rea, EdD, West Virginia University Cancer Institute

58. Quality Outcomes in Colon Cancer
Michelle Moskal, Watson Clinic Cancer and Research Center

71. Clinical Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Ani John, BSN, MPH, PhD, Roche Diagnostics
Top Abstract

72. Real-World Study of Factors Associated with Breast Conserving Surgery for Females Diagnosed with Early Stage Breast Cancer
Judy George, PhD, IBM Watson Health
Top Abstract

73. Diabetes Complications and Risks of Breast Cancer Recurrence Among Older Women
Jifang Zhou, MD, MPH, University of Illinois Chicago College of Pharmacy
Top Abstract

75. Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (Pts) Undergoing Systemic Therapy (Ctx): A Real World Experience
Sonali Agrawal, BS, Fox Chase Cancer Center
Top Abstract, Member Institution

77. Progression-Free Survival, Overall Survival, and Tumor Response for Patients Diagnosed with Small Cell Lung Cancer who Received First-Line Systemic Therapy
Junji Lin, PhD, Concerto Health AI

78. Prevalence and Correlates of Psychological Distress in Patients Enrolling on Phase I Clinical Trials Using the NCCN Distress Thermometer and Problem List
Alexandra Hunt, MS, Fox Chase Cancer Center
Member Institution

82. Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests Among Cancer Patients in the US
Kaushal Desai, PhD, Merck & Co., Inc.

83. Characteristics, Treatment Patterns, Healthcare Resource Use and Costs among Pediatric Patients Diagnosed with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Retrospective Database Analysis
Xiaoqin Yang, PhD, Merck & Co., Inc.

84. Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments
Ashley Tabah, MS, MPH, Celgene Corporation

85. Concurrent Chemoradiation Treatment Patterns for Stage III Non-small Cell Lung Cancer in Veterans
Anna Hung, PharmD, PhD, MS, Duke Cancer Institute
Member Institution

89. Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study
Shreekant Parasuraman, PhD, Incyte Corporation

91. Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients with Advanced Renal Cell
Frank Xiaoqing Liu, PhD, EMD Serono, Inc.

97. Psychosocial Support in Older Patients with Metastatic Breast Cancer (MBC) Treated at Community Centers
Bianca Lewis, BA, Fox Chase Cancer Center
Member Institution

101. Real-World Chemoradiotherapy Use Among Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Retrospective Observational Study
Lance Brannman, PhD, Massachusetts General Hospital Cancer Center
Member Institution

109. Results from a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization
Melissa Miller, PhD, MPH, Cancer Support Community Research & Training Institute

113. Real-World Adherence and Persistence of ALK Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Apar Kishor Ganti, MD, MS, Genentech, Inc.

Pre-Clinical Oncology

10. Combinatory Use of Circulating TERT Promoter Mutations and miR-122 Expression for Screening HBV-Related Hepatocellular Carcinoma
Trung Tat Ngo, PhD, 108 Military Central Hospital

Altering the Local Immune Landscape in Lung Cancer to Improve Checkpoint Inhibitor Therapy
Edwin Ramos Manuel, PhD, City of Hope National Medical Center
YIA, Member Institution

68. CD229 CAR-T Cells Eliminate Multiple Myeloma and Tumor Propagating Cells but Show Limited Targeting of Normal T Cells
Tim Luetkens, MD, Huntsman Cancer Institute at the University of Utah
YIA, Top Abstract, Member Institution

Quality Improvement

7. Utilization of a Distress Screening Tool in an Inpatient Hematopoietic Stem Cell Transplant Unit
Ivana Espinosa, APRN-BC, Sylvester Comprehensive Cancer Center

11. Baseline Assessment of Oncology Provider's Quality Improvement Knowledge in a MultiInstitutional Breast Cancer Quality Improvement Collaborative
Lindsey Kreutzer, MPH, Northwestern University Feinberg School of Medicine
Member Institution

22. Genetic Testing for At-Risk Patients with Colorectal and/or Pancreatic Cancer at our Institution, A Quality Improvement Project
Mina Shenouda, MD, Marshall University

32. Financial Toxicity: Building a Patient Centered Program
Kimberly Bell, RN, MBA, Cleveland Clinic
Member Institution

45. Prehabilitation Model of Care for the Patient with Breast Cancer
Karen Hock, PT, MS, CLT-LANA, The James Cancer Hospital and Solove Research Institute
Member Institution

70. Integration of Tobacco Treatment into Cancer Care at Stanford Health Care
Cindy Tran, MPH, Stanford Healthcare
Top Abstract

76. Are You Ready? Assessing Readiness to Implement Quality Improvement in Hospitals Participating in a Breast Cancer Collaborative
Lindsey Kreutzer, MPH, Northwestern University Feinberg School of Medicine
Member Institution

81. Lifeline for Oncology Patients - Telephone Triage
Sharon Steingass, RN, MSN, AOCN, Ohio State University James Cancer Hospital
Member Institution

96. A Tool Preparing Patients with Stage III Non-Small Cell Lung Cancer for Shared Decision-Making: Validating Acceptability and Usability
Courtney Ramus, MPH, Avalere Health

100. Fertility Preservation Discussion in Young Adults with Cancer: How Often Are We Documenting?
Yadav Pandey, MD, University of Arkansas for Medical Sciences

104. An Immediate Care Center for Oncology Patients “Symptom Management Doesn’t Require the Emergency Department”
Penny Moore, MSN, RN, OCN, NEA-BC, The James Cancer Hospital and Solove Research Institute
Member Institution

116. Retrospective Evaluation of VEGF Inhibitor-Associated Hypertension at a Community Cancer Center
Jasmin Eugene, PharmD, Our Lady of the Lake Regional Medical Center

123. The Efficacy of Cost-Effective Fixed Dose of Rasburicase Compared to Weight-Based Dose in Treatment and Prevention of Tumor Lysis Syndrome (TLS)
Ahmad Abu-Hashyeh, MBBS, Marshall Health

126. A Team-Based Model to Promoting Hospice Utilization in High Risk Oncology Patients Through Individual Care Plan Development
Mohammad Khan, DO, MSBS, Cleveland Clinic Taussig Cancer Institute

134. Rehabilitation of the Amyloidosis Patient
Elyse Redder, PT, CLT-LANA, The Ohio State University James Comprehensive Cancer Center
Member Institution